key: cord-0792426-y10k2cvc
authors: Synolaki, E.; Papadopoulos, V.; Divolis, G.; Gavriilidis, E.; Loli, G.; Gavriil, A.; Tsigalou, C.; Tsachouridou, O.; Sertaridou, E.; Rafailidis, P.; Pasternack, A.; Boumpas, D.; Germanidis, G.; Ritvos, O.; Metalidis, S.; Skendros, P.; Sideras, P.
title: Activin/Follistatin-axis deregulation is independently associated with COVID-19 in-hospital mortality
date: 2020-09-08
journal: nan
DOI: 10.1101/2020.09.05.20184655
sha: a1279545bae2a8bf7163828870b35caa8a2463b9
doc_id: 792426
cord_uid: y10k2cvc

Rationale: Activins are inflammatory and tissue-repair-related members of the TGF{beta}-superfamily that have been implicated in the pathogenesis of several immuno-inflammatory disorders including sepsis/acute respiratory distress syndrome (ARDS). We hypothesized that they might be of particular relevance to COVID-19 pathophysiology. Objectives: To assess the involvement of the Activin-Follistatin-axis in COVID-19 pathophysiology. Methods: Levels of Activins -A, -B and their physiological inhibitor Follistatin, were retrospectively analyzed in 314 serum samples from 117 COVID-19 patients derived from two independent centers and compared with common demographic, clinical and laboratory parameters. Optimal-scaling with ridge-regression was used to screen variables and establish a prediction model. Main Results: The Activin/Follistatin-axis was significantly deregulated during the course of COVID-19 and was independently associated with severity and in-hospital mortality. FACT-CLINYCoD, a novel disease scoring system, adding one point for each of Follistatin >6235 pg/ml, Activin-A >591 pg/ml, Activin-B >249 pg/ml, CRP >10.3 mg/dL, LDH >427 U/L, Intensive Care Unit (ICU) admission, Neutrophil/Lymphocyte-Ratio >5.6, Years of Age >61, Comorbidities >1 and D-dimers >1097 ng/ml, efficiently predicted and monitored fatal outcome independently of multiplicity and timing of sampling (AUC: 0.951{+/-}0.032, p<10-6). Validation in 35 samples derived from a third hospital indicated comparable AUC (0.958{+/-}0.086, p=0.032). Conclusion: This study unravels the link between Activin/Folistatin-axis and COVID-19 mortality and introduces FACT-CLINYCoD, a novel pathophysiology-based tool that copes with the dynamic and heterogeneous nature of COCVID-19, predicts disease outcome and supports clinical decision making. Prospective large-scale validation of this calculator, as well as investigation of the mechanisms linking Activin/Folistatin-axis to COVID-19 pathogenesis is warranted.

The evolving pandemic of COVID-19 constitutes presently the most prominent public-health issue worldwide. Thus far, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for more than 26 million COVID-19 cases and more than 870,000 deaths (1) . The initial phase of COVID-19 relates to viral pathogenic effects and is characterized by mild "flu-like" symptoms (2) . However, one week after onset-of-symptoms, ~20% of patients develop moderate-to severepneumonia often complicated by a cytokine-release-syndrome (CRS)-like hyperinflammatory reaction that can lead to ARDS and multi-organ failure, thereby increasing substantially the in-hospital mortality (2) (3) (4) (5) . Various comorbidities and aging negatively affect outcome of COVID-19 (3, 6) . Accumulating evidence indicate that excessive activation of innate-immune pathways, deregulated neutrophils and thrombotic microangiopathy characterize the maladaptive host-response that drives COVID-19 pathophysiology (7) (8) (9) (10) (11) . These pathomechanisms lead to rapid progression of hypoxemic respiratory failure and protean clinical manifestations, since almost any organ can be involved (12, 13) . Monitoring hospitalized patients, in the midst of multiple continuously changing parameters and shortage of validated and effective therapeutics, is challenging (2, 3, 5, 13) . Therefore, development of novel therapeutic strategies and bed-to-bench tools permitting dayto-day prediction of patient outcome would be of utmost importance for such dynamically evolving and clinically heterogeneous disease (12, (14) (15) (16) .

Activins-A and -B are members of the Transforming Growth Factor-β (TGF-β)superfamily implicated in the regulation of numerous aspects of inflammation and/or tissue remodeling (17) (18) (19) . Follistatin, a physiological Activin-inhibitor, binds to them almost irreversibly and induces endocytosis and proteolytic degradation thus modulating their bioavailability (20). Activins and Follistatin, are synthesized continuously in healthy tissues (21), however, in immuno-inflammatory conditions, epithelial, endothelial, interstitial stroma cells and different immune cells secrete higher levels that can be detected in serum and could function as biomarkers of local or systemic stress (17-19).

We have previously described increased levels of Activin-A and Follistatin in bronchoalveolar lavage (BAL) of ARDS patients (18, 22) . Moreover, we showed that . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint ectopic expression of Activin-A in murine lungs causes ARDS-like pathology (22), which shares cardinal features of COVID-19 pathophysiology. These include, strong early mobilization of neutrophils in the lung, alveolar epithelial and endothelial cellloss, establishment of a systemic hyper-coagulant state associated with increased tissue-factor (TF) mRNA levels and induction of a cytokine-storm like response characterized by high levels of IL-6 and TNFα (5, 7, 8, 18, 23) .

In view of these findings we hypothesized that the Activin/Follistatin-axis (A/F-axis) might be particularly relevant to COVID-19. To validate this hypothesis, we analyzed sera from COVID-19 patients and found that Activin-A, -B and Follistatin were significantly upregulated during the crucial period when patients deteriorate. Of note, A/F-axis components were independently associated with disease severity and in-hospital mortality. Based on that, we developed a simple clinical tool for the prediction and monitoring of COVID-19 outcome in real-life using Activin-A, -B, Follistatin and common clinical/laboratory parameters. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint

This is a retrospective study with a single endpoint, the final outcome (survival or death). Activin-A, -B and Follistatin, absolute-neutrophil-count (ANC), absolutelymphocyte-count (ALC), neutrophil/lymphocyte-ratio (NLR), C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, D-dimers, were analyzed in randomly acquired samples from patients which were diagnosed with COVID-19 from March 10, 2020 and had an outcome until July 7, 2020 (Supplementary Figure S1 ). Three national reference hospitals from distant regions of Greece participated in the study (University General Hospital of Alexandroupolis; "AHEPA" University General Hospital of Thessaloniki; "Attikon" University General Hospital of Athens).

Inclusion criteria were: a) adult patients (>16 years old), any gender, b) positive SARS-CoV-2 RT-PCR testing in nasopharyngeal swab or BAL, c) hospitalization due to COVID-19 at any disease stage, d) final disease outcome until July 7, 2020. Patients without available sample obtained before the 21 st day-of-disease were excluded (Supplementary Figure S1 ). The study protocol was approved by all relevant Institutional Ethical Committees and is aligned with the Helsinki declaration.

An initial cohort of 117 consecutive COVID-19 patients hospitalized at University Hospital, Alexandroupolis and "AHEPA" Hospital, Thessaloniki was endorsed and 314 samples were analyzed. Patients and sample characteristics are presented in Table 1 .

A second independent cohort of 28 consecutive COVID-19 patients derived from a distinct hospital ("Attikon" Hospital, Athens) contributing 35 samples was used for validation (Supplementary Table S1 ). Comorbidities considered were diabetes mellitus, arterial hypertension, dyslipidemia, obesity, atrial fibrillation, coronary disease, heart-failure, renal-failure, chronic obstructive pulmonary disease or asthma, immunosuppression (without a record of malignancy), autoimmunity and cancer. The disease-status (DS) of COVID-19 patients was classified as DS1 (mild), DS2 (moderate), DS3 (severe) and DS4 (critical) as suggested by Hadjadj et al. (10) (details in Supplementary Materials).

Common laboratory parameters including CRP, LDH, D-dimers, ANC, ALC and NLR were measured as part of standard of care. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint

Activin-A, -B and Follistatin levels in serum were measured using enzyme-linked immunosorbent assay (ELISA) (Ansh Labs, Webster, TX, USA) according to manufacturer's instructions.

To elucidate the role of A/F-axis molecules, we identified potent confounders from true predictors of outcome using general linear model. Prognostic value of predictors was validated; for that purpose, all independent variables of interest were transformed to binary ones through nominal optimal scaling along with discretization to two groups. Imputing of missing data was added, ridge-regression was selected for regularization and 10-fold cross-validation was added. Results were adapted to a point-system scoring, where one additive point was given for each parameter included in the unfavorable category as suggested after discretization; binary-regression was utilized to mathematically approach outcome probability. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint

To validate the hypothesis that the A/F-axis is linked to COVID-19 pathophysiology we analyzed serum levels of Activin-A, -B and Follistatin in a cohort of 117 COVID-19 patients. The day-of-symptom-onset (disease-day) was used to align the data derived from serum samples. Activin-A, -B and Follistatin, were substantially increased, particularly in samples derived from patients that eventually succumbed to infection (non-survivors) ( Table S3 ). Therefore, we concentrated our efforts to construct a sample-based rather than patient-based predictive model. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint Given that time from disease-onset is a key parameter for disease aggravation and hospital admission, we aimed to further elucidate how disease-time affects the correlation between A/F-axis and outcome. Of note, we noticed a more pronounced independent correlation of Follistatin with outcome (Supplemetary Figure S3 ). Furthermore, using binary-regression we concluded to a model incorporating Table S4 ). This model revealed the independent key role of Follistatin in predicting outcome and provided a good estimate; however, it did not reach gold standard level (ROC analysis, Supplementary Figure S4 ) and therefore we sought to further improve it.

We hypothesized that the erratic and heterogeneous behavior of COVID-19 should be mirrored by analogous fluctuations in the profiles of key biomarkers. We therefore opted to investigate the correlation between different biomarkers in the entire sample collection. The correlation of Activin-B levels to LDH, and Activin-A levels to CRP and NLR are shown as representative comparisons ( Figure 3 ). In Activin-B vs LDH comparison, some samples exhibited good correlation but others did not.

Notably, in Activin-A vs CRP or NLR comparisons, the parameters did not correlate at all. To understand better this finding, we highlighted in similar plots the groups of samples derived from non-survivor patients AL022, AL034, AL035, AL062, AL063 and AX112 for which multiple samplings were available ( Figure 3 , lower panel).

Remarkably, this depiction revealed marked phenotypic heterogeneity among patients and highlighted the dynamic heterogeneity among samples collected from the same patient at different disease-days. For example, for patients AL022 and AL035, disease progression and eventual death were associated with concordant changes in Activin-B and LDH levels. However, patients AL063 and AX112, in addition to A/F-axis components, were characterized by substantial changes in CRP levels, and for patients AL035 and AL062 disease progression was associated with eventual is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint reduction of CRP and NLR. Finally, patient AL034 was characterized by borderline levels of Activins -A and -B and high levels of CRP. Interestingly, patient AL022, who received a dose of Tocilizumab on disease-day 11 (one day after admission), exhibited for ~10 days transient reduction of LDH, CRP, NLR, Activin-A and -B values, before reverting and dying on disease-day 28. Therefore, in addition to intrinsic phenotypic variability among patients, treatments could also influence biomarker profile during hospitalization. From all the above we concluded that a broader spectrum of biomarkers, including both early and later modulated ones, had to be integrated to develop a meaningful disease-monitoring scoring system.

Considering the dynamically evolving and heterogeneous phenotypic changes characterizing COVID-19 progression, to improve the capacity of our scoring system to discriminate survivors from non-survivors, in a simple and clinically meaningful manner, we converted all continuous variables to binary through selection of optimal cutoffs. Optimal-Scaling procedure was performed along with ridgeregression to investigate any parameter that could independently predict outcome (Supplementary Table S5 and Supplementary Figure S5) . We concluded in a 10parameter model as presented in Table 2 and Supplementary Table S6 . Based on these data, we constructed a ten-point scoring-system where one additive point was arbitrarily given for each parameter included in the unfavorable category as suggested after discretization, namely if Follistatin >6235 pg/ml, Activin-A >591 pg/ml, Activin-B >249 pg/ml, CRP >10.3 mg/dL, LDH >427 U/L, ICU admission, NLR >5.6, Years of Age >61, Comorbidities >1 and D-dimers >1097 ng/ml. We evaluated this score with ROC analysis, yielding to an AUC value of 0.951±0.032 (p<10 -6 ), that indicates outstanding discrimination in foretelling survivors from non-survivors ( Figure 4A ). This score was titled FACT-CLINYCoD, being an acronym of F(ollistatin),

A score ≥4 has 90.8% sensitivity and 87.5% specificity to predict fatal outcome, whereas a score ≥5 has 81.5% sensitivity and 95.7% specificity. The FACT-CLINYCoD score distinguishes survivors from non-survivors at admission and outcome and monitors accurately disease progression independently of disease-day . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint or status ( Figure 4C ,D,E). Removal of the A/F-axis components from FACT-CLINYCoD yields to a 7-point scoring system with a comparable AUC (0.938, 95% CI 0.902-0.974); however, its substantially reduced sensitivity to predict >50% probability of fatal outcome (52.3%) underlies clearly the additive value of Activins and Follistatin.

The probabilities of death calculated at different disease-days in non-surviving patients AL022, AL034, AL035, AL062, AL063 and AX112 are shown in Figure 3 , next to each time sample analyzed. Interestingly, some of these patients had very high scores already at first sampling, however, others, such as AX112 and AL035 had low scores at admission and either gradually or rapidly deteriorated and eventually died.

The latter type of patients highlights the value of continuous monitoring COVID-19.

In all cases, the FACT-CLINYCoD system was able to monitor clinical deterioration and in the case of AL022, was not deceived by the dramatic reduction of LDH, Activin-A and NLR after administration of Tocilizumab ( Figure 3 , low panel) and kept indicating >85% probability of death.

The FACT-CLINYCoD score was validated using an independent cohort of 28 consecutive patients contributing 35 random samples. Although this small cohort differed significantly from the initial regarding age, disease-status, treatments, sampling approach, and day from disease-onset (Supplementary Table S1 ), a comparable AUC was observed (0.958, 95% CI: 0.872-1.000, P=0.032, Figure 4B ).

The value of FACT-CLINYCoD score in supporting treatment decision algorithms was evaluated, as indicated by ROC analysis (Supplementary Figure S6 ). More specifically, Optimal-Scaling procedure was performed along with ridge-regression to investigate any treatment that could independently predict outcome. Hydroxychloroquine, azithromycin, antibiotics other than azithromycin, Lopinavir/Ritonavir, low molecular weight heparin (LMWH), anakinra and corticosteroids were found to be independently associated with survival when treatment commenced at FACT-CLINYCoD scores <3 (Supplementary Table S7 ). The scoring system proposed herein is thus promising in guiding timely treatment administration and predicting favorable . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint response to therapeutic intervention. However, the small number of patients dictates caution in interpreting these findings.

This study provides evidence suggesting that inflammation and tissue stress-related proteins Activins-A,-B, and their natural inhibitor Follistatin are tightly associated with severity and outcome of COVID-19. Their upregulation was prominent in nonsurvivors and was independently related to in-hospital mortality. Of note, combination of A/F-axis components with common clinical and laboratory parameters permits prediction of COVID-19 outcome throughout the course of the disease.

Identification of high-risk patients and death-prediction are of particular importance especially in strained health-care systems. Hence, several studies attempted to develop scoring systems to predict disease severity and mortality as early as possible (4, 6, 14, 15, (24) (25) (26) . Most of these models were based on demographic parameters and instantaneous evaluation of subjective symptoms (i.e. dyspnea) combined with single measurements of common laboratory markers, such as neutrophil or lymphocyte counts, LDH, CRP and several proinflammatory cytokines (4, 6, 14, 15, 24, 26, 27) . These models are undoubtedly useful; however, they place main emphasis on prediction of final-outcome at admission and thus may fail to predict some non-survivors most likely due to the complex and often erratic development of COVID-19 (exemplified by patients AX112 and AL035) and the downregulation of key biomarkers at later disease stages ( Figure 3) . Moreover, most of the previous predictive systems were developed based on patient characteristics of the first waves of COVID-19, i.e. older with several comorbidities and it cannot be excluded that the demographics of the next waves will be different.

Considering the above, we exploited three novel components to develop a more dynamic COVID-19 monitoring system. First, we determined levels of Activins and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . which are key characteristics of COVID-19 pathophysiology (7, 8, 18, 22, 28) . We reasoned that upregulation of A/F-axis could indicate tissue-damage in the lung, vasculature or other vital peripheral tissues, thus complementing information derived from other biomarkers reporting tissue-damage (i.e. LDH) or coagulation/vascular injury (i.e. D-dimers) (2, 15, 25, 26) . Second, we used a sampleinstead of patient-based analytic strategy, since regression models demonstrated that kinetics of A/F-axis components correlated independently with disease-day at sampling, and not with number of samples/patient or patient's origin. Third, we sought to exploit the differences in the kinetics of A/F-axis components and other classical biomarkers such as NLR, CRP, LDH and D-dimers ( Figure 2 ) to develop a monitoring system that will not only make early predictions but, equally important, will allow readjustment of predictions during disease progress. Our goal was to provide a monitoring system that could assist real-time decision making in the context of a complex and erratic disease, such as COVID-19 (2, 3, 5, 12, 13, 16).

In the pre-COVID-19 era, the A/F-axis was evaluated as predictor of outcome in critical care patients (29). Thus, increased levels of Activin-A and -B in sera from ICU patients with acute respiratory failure could predict 90-days and 12-months survival with ~80% accuracy; Follistatin did not provide any extra predictive value (29). A/Faxis components were measured also in sera of critically-ill, influenza-A (H1N1), patients; Despite the increased Activin-A, -B and Follistatin, no significant association with disease severity was established (30). However, while preparing the current manuscript, consistent with our conclusions, a preprint study reported Follistatin among the circulating markers of endothelial damage associated with in-hospital mortality in a small number of COVID-19 patients (31) .

Although the exact mechanism linking Activins to COVID-19 pathogenesis remains unknown, the importance of A/F-axis in the disease is reflected on the predictive is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. Figures S3, S5) . Moreover, removal of the triad Activin-A, -B and Follistatin from FACT-CLINYCoD leads to substantial reduction in sensitivity to predict >50% probability of fatal outcome, further illustrating the link of A/F-axis to COVID-19 final outcome and its added-value in the scoring system as deduced from binaryregression and ridge-regression coefficients (Supplementary Table S4 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint each group and the non-randomized nature of this study, should be considered at the moment with caution. Nevertheless, preliminary results showed favorable outcome when LMWH was commenced at FACT-CLINYCoD score <3. This is consistent with emerging clinical data linking reduced mortality with early administration of LMWH in all hospitalized COVID-19 patients (37) and supports the detrimental role of immunothrombosis in COVID-19 (7).

In conclusion, A/F-axis dysregulation is tightly associated with poor outcome of COVID-19. FACT-CLINYCoD, a novel pathophysiology-driven monitoring system that incorporates A/F-axis components and classical biomarkers, enables dynamic prediction of disease outcome and may support real-time medical decision.

Prospectively, large-scale, multinational validation of this calculator, as well as investigation of the mechanisms linking A/F-axis to COVID-19 pathogenesis is absolutely warranted. These may offer new and highly needed strategies for management of COVID-19 pandemic, given the fact that despite extensive efforts, safe and effective vaccines against SARS-CoV-2 might take long before they can be administered to people.

We thank Dr. Apostolos Vasileiou for technical assistance and Dr. Mika Laitinen for critical reading of the manuscript. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint

The disease-status (DS) of COVID-19 patients was classified based on the adaptation of the Sixth Revised Trial Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance, as described previously (1) . Mild cases (DS1) were defined as mild clinical symptoms (fever, myalgia, fatigue, diarrhea) and no sign of pneumonia on thoracic X-Ray or/and CT scan. Moderate cases (DS2) were defined as clinical symptoms associated with dyspnea and radiological findings of pneumonia on thoracic X-Ray or/and CT scan, and requiring a maximum of 3 L/min of oxygen.

Severe cases (DS3) were defined as respiratory distress requiring more than 3 L/min of oxygen and no other organ failure. Critical cases (DS4) were defined as respiratory failure requiring mechanical ventilation, shock and/or other organ failure that require an intensive care unit (ICU).

Activin-A, -B and Follistatin levels in serum were measured using enzyme-linked immunosorbent assay (ELISA) (Ansh Labs, Webster, TX, USA) according to manufacturer's instructions. For Activin-A (Cat# AL-110) limit of detection was 65 pg/ml and dynamic range 0.1-10 ng/ml. For Activin-B (Cat# AL-150) limit of detection was 4.35 pg/ml and the dynamic range 12.7-1400 pg/ml. For Follistatin (Cat# AL-117) limit of detection was 180 pg/ml and dynamic range 0.612-20 ng/ml. Baseline levels of Activin-A, -B and Follistatin in 19 normal, pre-COVID-19 sera, were 404±193, 144±53 and 2656±1784 pg/ml, respectively, very similar to those previously reported by others using the same reagents (2).

To search for biases, we compared all measured parameters between patients and samples using either Pearson's χ 2 or a two-sample independent t-test in case of discrete and continuous variables respectively; in case of statistically significant increase in homogeneity of variance, as checked by Levene's test, Mann-Whitney U test was additionally performed. ANOVA along with Tuckey's post-hoc test was used to compare more than two groups (namely samples derived from days 1-7, 8-14 and 15+) in case of continuous variables distributed uniformly; else, Kruskall-Wallis test is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint was alternatively used. General linear model was used to dissect true independent correlations of the A/F axis molecules from potent confounders.

Initially, multivariate analysis of risk factors for outcome was performed with binary logistic regression over imputed data; outcome was considered as a dependent variable and every parameter of interest was treated as a potent independent parameter (the probability for stepwise entry and removal were set to 0.05 and 0.10 accordingly, the classification cutoff was set to 0.5 and the maximum number of iterations was set to 20). Models including parameters with tolerance <0.4 (variance inflation factor >2.5), as deduced from corresponding linear regression analysis assessing numerical values to outcome, were rejected to avoid collinearity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. Supplementary Table S4 by dividing the difference between -95% CI from +95%CI with 3.92). ROC analysis revealed good AUC values for the above mentioned calculator (Supplemental Figure 3) .

Optimal Scaling procedure along with ridge regression yielded to a 10-parameter model as presented in Supplementary Table S5 and Figure 4 . Based on these data, we constructed a ten point-system scoring where one additive point was given for each parameter included in the unfavorable category as suggested after discretization, namely if Follistatin >6235 pg/ml, Activin-A >591 pg/ml, Activin-B >249 pg/ml, NLR >5.6, LDH >427 U/L, CRP >10.3 mg/dL, D-dimers >1097 ng/ml, Age is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint stands for the probability of death at the time of sampling; ±95% CI of p lie between e -6.547+1.330*score /(1+e -6.547+1.330*score ) and e -5.849+1.330*score /1+e -5.849+1.330*score ) ( Table 2) .

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 8, 2020. . https://doi.org/10.1101/2020.09.05.20184655 doi: medRxiv preprint

WHO Coronavirus Disease (COVID-19) Dashboard

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Interleukin-6-based mortality risk model for hospitalised COVID-19 patients

HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 ARDS

Extrapulmonary manifestations of COVID-19

Severe Covid-19

COVID-19 disease: an autopsy study with clinical correlation

China Medical Treatment Expert Group for COVID-19. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19

Scoring systems for predicting mortality for severe patients with COVID-19

An interpretable mortality prediction model for COVID-19 patients

An inflammatory cytokine signature predicts COVID-19 severity and survival

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Circulating Markers of Angiogenesis and Endotheliopathy in COVID-19

The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis

Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia

The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair

Key role for activin B in cellular transformation after loss of the von Hippel-Lindau tumor suppressor

Supplementary Table S7. Optimal survival using FACT-CLINYCoDscore cut-offs in treatment options

Responders (%) Cut-off (stochastic) ‡

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Serum Levels of Activins, Follistatins, and Growth Factors in Neoplasms of the Breast: A Case-Control Study